Breakthrough Oral Cancer Detection Method Unveiled
On July 8, 2023, researchers introduced a new diagnostic tool for oral cancer called qMIDS (quantitative malignancy diagnostic system). This painless alternative to traditional biopsy delivers results in just one hour with over 95.5% accuracy. The technology works by analyzing the expression of four specific genes linked to cancerous processes.
How the Test Works and Study Results
The diagnostic procedure is completely painless: a special brush is used to collect a sample, eliminating the need for any surgical intervention. The study tested the third version of the qMIDS system on 545 patients with potentially malignant lesions. A control sample is taken from healthy oral mucosa, and the rate of false positives and false negatives was less than 5%.
Since 1990, the incidence of and mortality from oral cancer have more than doubled, driven by factors such as:
- smoking
- alcohol consumption
- human papillomavirus
The research team is now working to commercialize the qMIDS system, expecting it to become widely available in clinical settings within the next two years.
As researcher Muy-Teck Teh explained: 'The biological signal from the four target genes is so strong that it can be easily detected even in superficial cells, without deep surgical intervention.'
The scientific paper describing this technology was published in the journal Biomarker Research.
The introduction of qMIDS could fundamentally change early detection strategies for oral cancer, a particularly urgent goal given rising incidence rates. Its painless nature and high accuracy may encourage more patients to undergo screening, ultimately helping reduce mortality from this disease. Successful commercialization of qMIDS in the coming years could also pave the way for similar diagnostic innovations in other medical fields.
As the fight against cancer continues to evolve, recent advancements in treatment methods are gaining attention. For instance, a new study has revealed that scientists have found a way to inhibit cancer cell migration by 90% in pancreatic tumors, which could significantly impact patient outcomes. To learn more about this promising development and its potential implications for cancer therapy, visit this article.